Tabitha Rees
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
- Inflammatory Bowel Disease
Papers in
-
- COVID-19 Clinical Research Studies 5
- SARS-CoV-2 and COVID-19 Research 3
- Genetics 6
- Genetic Associations and Epidemiology 6
- Journals
- Nature (4 papers)The Lancet (3 papers)Nature Communications (1 paper)Nature Immunology (1 paper)Human Genetics and Genomics Advances (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Tabitha Rees
12 papers receiving 2.1k citations
Tabitha Rees's Hit Papers
Peers
Comparison fields: 5 of 94
- Infectious Diseases 1.3k
- Genetics 554
- Applied Microbiology and Biotechnology 34
- Neurology 159
- Internal Medicine 28
Countries citing papers authored by Tabitha Rees
This map shows the geographic impact of Tabitha Rees's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tabitha Rees with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tabitha Rees more than expected).
Fields of papers citing papers by Tabitha Rees
This network shows the impact of papers produced by Tabitha Rees. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tabitha Rees. The network helps show where Tabitha Rees may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 5 | 2021 | 213 | |
| 6 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 7 | 2022 | 74 | |
| 8 | Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease Hit paper breakdown → | 2024 | 65 |
| 9 | 2023 | 60 | |
| 10 | 2023 | 35 | |
| 11 | 2022 | 29 | |
| 12 | 2024 | 8 | |
| 13 | 2021 | 0 |
About Tabitha Rees
Tabitha Rees is a scholar working on Infectious Diseases, Genetics, Neurology, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 13 papers that have together received 2.2k indexed citations. Recurring topics across this work include Genetic Associations and Epidemiology (6 papers), COVID-19 Clinical Research Studies (5 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Long-Term Effects of COVID-19 (2 papers). The work is most often cited by research in Infectious Diseases (1.3k citations), Genetics (554 citations), Applied Microbiology and Biotechnology (34 citations), Neurology (159 citations) and Internal Medicine (28 citations). Tabitha Rees has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as Nature, The Lancet, Nature Communications, Nature Immunology and Human Genetics and Genomics Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.